psychosis Archives -

Acadia Pharma’s attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer’s disease-related

FDA panel turns down Acadia’s Nuplazid for Alzheimer’s psychosis

https://pharmaphorum.com/news/fda-panel-turns-down-acadias-nuplazid-for-alzheimers-psychosis/

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231,

Cerevel soars on first data for muscarinic schizophrenia drug

https://pharmaphorum.com/news/cerevel-soars-on-first-data-for-muscarinic-schizophrenia-drug/

Exscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the

Exscientia starts trials of AI-designed Alzheimer’s drug

https://pharmaphorum.com/news/exscientia-starts-clinical-trials-of-ai-designed-alzheimers-drug/

Acadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its

Acadia puts blame on FDA as Nuplazid rejected for dementia

https://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/

psychosis